<DOC>
	<DOCNO>NCT02273713</DOCNO>
	<brief_summary>Oesophagogastric cancer major cause cancer relate mortality , overall 5-year survival rate 10 % worldwide patient often diagnose locally advanced metastasized disease first presentation . For advanced oesophagogastric cancer fluoropyrimidines backbone palliative chemotherapy commonly use 2- 3-drug combination . However , clinical practice progression first line therapy , substantial number oesophagogastric cancer patient may able start second line chemotherapy due rapid clinical deterioration . Therefore , new triplet high anti-tumor activity low toxicity urgently need . Given activity capecitabine oxaliplatin contain regimen potential taxanes oesophagogastric cancer , investigator propose phase I study combine capecitabine oxaliplatin Nab-paclitaxel . Solvent-based taxanes ( paclitaxel , docetaxel ) cause severe toxicity active agent also solvent like cremophor . Nab-paclitaxel ( Abraxane ) solvent-free formulation paclitaxel encapsulate albumin . It require premedication corticosteroid antihistamines prevent risk solvent-mediated hypersensitivity reaction . This new formulation improve safety profile , allow high dose short infusion duration , produce high tumor drug concentration . It proven activity breast cancer , non small lung cancer pancreatic cancer , well gastric cancer model .</brief_summary>
	<brief_title>The Addition Nab-paclitaxel ( Abraxane ) First Line Treatment Metastasized Oesophagogastric Carcinoma ( ACTION )</brief_title>
	<detailed_description>Phase 1 : To assess safety tolerability Nab-paclitaxel add oxaliplatin capecitabine currently optimal dos . Phase 2 : To determine anti-tumor activity Nab-paclitaxel co-administered oxaliplatin capecitabine patient irresectable metastasized oesophagogastric cancer term progression free survival . Study design This single-center , open label , dose finding , phase I/II study . Intervention In phase I part study , dose nab-paclitaxel combination capecitabine oxaliplatin escalate fixed increment accord dose escalation scheme outline Dose level Nab-paclitaxel Capecitabine Oxaliplatin Minimum Day 1 8 14 day Day 1 8 number patient -1 40 mg/m2 1000 mg/m2 65 mg/m2 - 1 . ( start ) 60 mg/m2 1000 mg/m2 65 mg/m2 3 2 . 80 mg/ m2 1000 mg/m2 65 mg/m2 3 3 . 100 mg/ m2 1000 mg/m2 65 mg/m2 3 4 . 120 mg/ m2 1000 mg/m2 65 mg/m2 3 In phase II part study maximum tolerate dose phase I part study use combination fix dosage capecitabine oxaliplatin ; nab-paclitaxel day 1 8 accord Maximum Tolerated Dose ( MTD ) phase 1 part study combine capecitabine 14 day 1000mg/m2 twice daily oxaliplatin day 1 8 65mg/m2 .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Patients must provide write informed consent accord ICH/GCP , national/local regulation prior screen procedure . Patients histologically confirm diagnosis metastatic irresectable carcinoma stomach oesophagus Patients metastatic irresectable carcinoma stomach oesophagus pretreated chemotherapy radiotherapy irresectable metastatic disease . Measurable disease assess RECIST 1.1 ECOG ( WHO ) performance status 02 Patient adequate bone marrow organ function If female patient childbearing potential : negative serum pregnancy test , If sexually active , patient must agree use contraception . Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial Prior systemic treatment metastatic irresectable stomach oesophageal cancer . Evidence disease progression within 3 month completion adjuvant neoadjuvant treatment contain capecitabine and/or oxaliplatin . History hypersensitivity nabpaclitaxel , capecitabine oxaliplatin . All target lesion radiation field without documented disease progression . WHO 24 Use investigational drug within 30 day enrollment . Patient known brain metastasis , unless previously treat wellcontrolled least 3 month ( define clinically stable , oedema , steroid stable 2 scan least 4 week apart ) . History malignancy last 5 year . Patients prior history situ cancer basal squamous cell skin cancer eligible . Patients malignancy eligible cured surgery alone surgery plus radiotherapy continuously diseasefree least 5 year . Patients willing avoid consumption Seville orange , grapefruit grapefruit juice grapefruit hybrid , pomelo exotic citrus fruit entire study . Patient currently treat drug know strong inhibitor inducer CYP3A4 CYP2C8 , discontinue switched different medication 7 day prior start study treatment duration study . Patient active , uncontrolled bacterial , viral fungal infection ( ) require systemic therapy . Patient known historical active infection human immunodeficiency virus ( HIV ) , hepatitis B hepatitis C. Patient concurrent severe and/or uncontrolled medical condition would , investigator 's judgment contraindicate patient participation clinical study ( e.g . hematological , cardiovascular , lung disease etc ) Patient enrol clinical protocol investigational trial primary endpoint . Patients investigator ' opinion may unwilling , unable unlikely comply requirement study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Esophageal cancer</keyword>
	<keyword>Metastasized</keyword>
	<keyword>Nab-paclitaxel</keyword>
	<keyword>Toxicity</keyword>
	<keyword>First line treatment</keyword>
	<keyword>Phase Ib/II</keyword>
</DOC>